Table 3. Summary association results of PRPF6 rs8126213 (G > A) in all of the eight lung cancer GWASs.
| Study population | Sample size | Overall (N = 14463) | AD (N = 4862) | SQ (N = 3897) | ||||
|---|---|---|---|---|---|---|---|---|
| Cases | Controls | OR (95% CI)* | P* | OR (95% CI)* | P* | OR (95% CI)* | P* | |
| TRICL | 12160 | 16838 | 0.89 (0.85–0.94) | 1.65E-05 | 0.88 (0.81–0.95) | 9.0E-04 | 0.88 (0.82–0.96) | 2.20E-03 |
| ICR | 1952 | 5200 | 0.94 (0.85–1.05) | 0.303 | 0.94 (0.77–1.15) | 0.572 | 0.92 (0.77–1.20) | 0.374 |
| MDACC | 1150 | 1134 | 0.87 (0.73–1.04) | 0.120 | 0.87 (0.71–1.07) | 0.199 | 0.84 (0.64–1.11) | 0.219 |
| IARC | 2533 | 3791 | 0.91 (0.81–1.01) | 0.075 | 0.93 (0.76–1.13) | 0.456 | 0.91 (0.78–1.06) | 0.238 |
| NCI | 5713 | 5736 | 0.87 (0.81–0.95) | 8.36E-04 | 0.86 (0.77–0.97) | 0.012 | 0.85 (0.75–0.96) | 7.92E-03 |
| Toronto | 331 | 499 | 0.86 (0.62–1.20) | 0.379 | 0.77 (0.47–1.27) | 0.314 | 0.97 (0.51–1.83) | 0.923 |
| GLC | 481 | 478 | 0.83 (0.63–1.10) | 0.195 | 0.67 (0.45–0.98) | 0.041 | 1.01 (0.64–1.58) | 0.979 |
| Harvard and deCODE | 2303 | 27350 | 0.98 (0.89–1.09) | 0.772 | 0.97 (0.84–1.12) | 0.683 | 1.02 (0.82–1.26) | 0.875 |
| Harvard | 984 | 970 | 0.97 (0.79–1.20) | 0.801 | 0.94 (0.74–1.18) | 0.576 | 0.97 (0.68–1.40) | 0.886 |
| deCODE | 1319 | 26380 | 0.99 (0.87–1.12) | 0.850 | 0.99 (0.82–1.20) | 0.940 | 1.04 (0.80–1.37) | 0.761 |
| All combined | 14463 | 44188 | 0.91 (0.87–0.95) | 6.36E-05 | 0.91 (0.87–0.95) | 1.70E-03 | 0.90 (0.83–0.97) | 4.80E-03 |
Abbreviations: TRICL: GWASs datasets combined by six GWASs of ICR, MDACC, IARC, NCI, Toronto and GLC; ICR: the Institute of Cancer Research Genome-wide Association Study, UK; MDACC: the MD Anderson Cancer Center Genome-wide Association Study, US; IARC: the International Agency for Research on Cancer Genome-wide Association Study, France; NCI: the National Cancer Institute Genome-wide Association Study, US; Toronto: the Lunenfeld-Tanenbaum Research Institute Genome-wide Association Study, Toronto, Canada; GLC: German Lung Cancer Study, Germany; Harvard: Harvard Lung Cancer Study, US; deCODE: Icelandic Lung Cancer Study, Iceland; AD: adenocarcinoma; SQ: squamous cell carcinoma; *Meta-analysis of results from additive model.